Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer

Bookmark and Share
Published: 8 Oct 2016
Views: 2566
Rating:
Save
Dr Gabriel Hortobagyi - MD Anderson, Houston, USA

Dr Hortobagyi talks to ecancertv at ESMO 2016 about how the addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer.

Read the news story or watch the press conference video for more.

Supported by a grant from Pfizer Inc.